Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer

Fig. 6

PRMT5 inhibition and FKA treatment inhibited BC growth in vivo. a Cell viability measured in wild-type or Y304/F580 mutated PRMT5 T24 (left) and UMUC3 (right). The inhibition effect of FKA was tested in different groups. Data are presented as the mean ± SD of three replicates. *** p < 0.001, **** p < 0.0001, using one-way ANOVA test. b FKA induced cell apoptosis rate in wild-type, and Y304/F580 mutated PRMT5 T24 (upper) and UMUC3 (lower) cells. Data are presented as the mean ± SD of three replicates. *** p < 0.001, **** p < 0.0001, using Student’s t-test. c Subcutaneous tumorigenesis in Balb/c nude mice injected with control UMUC3 cells or PRMT5 knockdown UMUC3 cells, and FKA was injected intraperitoneally. d Tumor volume was recorded during tumor growth in different groups of nude mice. Data are presented as the mean ± SD of three replicates. **** p < 0.0001, using one-way ANOVA test. e Tumor weight measured from different groups of nude mice. Data are presented as the mean ± SD of three replicates. *** p < 0.001, **** p < 0.0001, using Student’s t-test. f Arginine methylation changed at the third arginine of histone 2A and histone 4 in the subcutaneous tumor. g BC regulon gene changes in the control, PRMT5 knockdown, and FKA treated subcutaneous tumor tissues. h Graph abstract of FKA targeting PRMT5-modulated histone arginine methylation in BC

Back to article page